Cancer. Infectious Disease. Liquid Biopsy.

 

Our Diagnostics Pipeline

Light‑Hope advances two high‑impact diagnostic domains—Early Cancer Detection and Infectious Disease Diagnostics—each powered by the same hybrid molecular + AI platform. Both pipelines leverage RNA liquid biopsy, precision PCR, and cold‑chain‑free lyophilized formulation to deliver globally accessible testing.

image_gen_bd833886-6104-4181-8bb3-2111950b500e
 EARLY CANCER DETECTION

Light‑Hope develops PCR‑based IVD products that use non‑coding RNA biomarkers in liquid biopsy to detect cancer at its earliest stages—long before imaging can.

Our cancer pipeline includes breast cancer (in analytical/clinical validation) and multiple forthcoming assays across liver, ovarian, lung, pancreatic, and prostate cancers, with a long‑term goal of multi‑cancer early detection (MCED).

image_gen_886c4193-cec1-4f68-8501-9c830e940693
 INFECTIOUS DISEASE DIAGNOSTICS

Our infectious disease pipeline focuses on developing ambient‑stable PCR reagents optimized for tropical climates—achieving ≥18‑month stability at 40 °C and enabling cold‑chain‑free deployment.

These reagents support scalable, low‑cost panels for high‑priority diseases including TB, HIV, and HPV, validated through India‑based cGMP partners and LMIC diagnostic networks.                                                             

LEAD DIAGNOSTIC PROGRAM

Early Breast Cancer Detection

Mammography frequently fails to detect early‑stage breast cancer—especially in younger women with dense breast tissue, where incidence has been rising at an alarming rate. These limitations create a diagnostic blind spot at the exact moment when early intervention is most effective.

Light‑Hope’s first PCR‑based IVD product is designed for early detection of all major breast cancer subtypes using non‑coding RNA biomarkers circulating in blood. This assay identifies early tumor biology long before imaging can, offering a more sensitive and accessible approach to early diagnosis. 

 

EXPLORE PARTNERSHIP OPTIONS
EarlyDetectionChallenge-1cropped
image_gen_3894be3c-b82a-461c-9b19-187043e1bc02
 ER+/-

Tumors that either express (ER+) or lack (ER–) estrogen receptors, influencing hormone‑based treatment response.

image_gen_bcc7b3f2-2d39-473a-84e9-cba195c14e5a
 PR+/-

Tumors with (PR+) or without (PR–) progesterone receptors, helping refine prognosis and guide hormone therapy.

image_gen_2474a7c6-8cc0-4478-94a2-bb5164bace3a
 HER2+/-

Tumors with high (HER2+) or normal (HER2–) HER2 protein levels, determining eligibility for targeted HER2 therapies.

image_gen_27da7723-0c2d-4544-b1db-f052fd241e88
 TRIPLE NEGATIVE

Tumors lacking ER, PR, and HER2 expression, often more aggressive and requiring non‑hormonal, non‑HER2‑targeted treatment approaches.

NEXT-GENERATION DIAGNOSTICS

RNA Biomarkers in Liquid Biopsy

Light‑Hope’s approach uses non‑coding RNA biomarkers circulating in blood to detect early tumor biology. Unlike imaging, RNA biomarkers reflect real‑time molecular activity, enabling detection:

      • Before tumors are visible

      • Across all major breast cancer subtypes

      • With high sensitivity and specificity

      • Through a simple, non‑invasive blood draw

Combined with precision PCR and our cold‑chain‑free lyophilized formulation, this test is engineered for both clinical accuracy and global accessibility.

LHD LEAD PROGRAM
Copilot_20260512_202443
GLOBAL ACCESSIBILITY

Cold-Chain-Free Diagnostics

Light‑Hope overcomes global access barriers by developing cost‑effective, cold‑chain‑free diagnostic formulations through advanced lyophilization.

By freeze‑drying PCR and RNA‑based assays into stable, shelf‑ready formats, we eliminate refrigeration requirements, reduce logistics costs, and enable reliable early‑detection testing in any setting—from high‑resource labs to remote or low‑infrastructure environments.

This approach makes advanced molecular diagnostics both scalable and globally deployable, expanding access to early cancer detection where it’s needed most. 

Partner with Light‑Hope to Build Globally Accessible Diagnostics 

EXPLORE PARTNERSHIP OPTIONS